Literature DB >> 10788763

Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex.

G L Gessa1, P Devoto, M Diana, G Flore, M Melis, M Pistis.   

Abstract

The aim of the present study was to compare the effects of the typical antipsychotic haloperidol and the atypical antipsychotics clozapine and olanzapine on both extracellular dopamine (DA) levels in the medial prefrontal cortex (mPFC) as well as electrical activity of mesoprefrontal DA (mPFC-DA) neurons. Extracellular single unit recordings and microdialysis experiments were carried out in different groups of chloral hydrate anesthetised rats under identical experimental conditions. Intravenous administration of haloperidol, clozapine, and olanzapine increased the firing rate and burst activity of antidromically-identified mPFC-DA neurons; maximal increase in firing rate of approximately 140, 155, and 70 %, was produced by haloperidol, clozapine, and olanzapine at doses of 0.2, 2.5, and 1 mg/kg, i.v., respectively. Intravenous administration of the same doses increased extracellular DA levels in mPFC by 20%, 190%, and 70%, respectively. Moreover, while haloperidol and olanzapine increased extracellular levels of the deaminated DA metabolite DOPAC, by 60% and 40%, respectively, clozapine was totally ineffective. The D1 receptor antagonist SCH 23390 modified neither DA output nor neuronal firing. To determine whether the effect of the three antipsychotics on DA release might depend on a direct action on the mPFC, rats were perfused locally via inverse dialysis in the mPFC at concentrations ranging from 10(-6) to 10(-4)M. While clozapine and olanzapine increased extracellular DA concentrations by up to 400% of basal level, haloperidol was totally ineffective. The results obtained from this study indicate that the rank potency of the three antipsychotics in stimulating the firing rate of DA neurons projecting to mPFC, correlates with their affinity for D2 receptors and doses used clinically. On the other hand, their stimulating effect on DA release does not correlate with their effect on neuronal firing but depends on a direct action on the mPFC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10788763     DOI: 10.1016/S0893-133X(00)00087-7

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  25 in total

Review 1.  Regional differences in the action of antipsychotic drugs: implications for cognitive effects in schizophrenic patients.

Authors:  Richard J Beninger; Tyson W Baker; Matthew M Florczynski; Tomek J Banasikowski
Journal:  Neurotox Res       Date:  2010-04-08       Impact factor: 3.911

Review 2.  Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.

Authors:  Richard S Jope; Myoung-Sun Roh
Journal:  Curr Drug Targets       Date:  2006-11       Impact factor: 3.465

Review 3.  Imaging genomics and response to treatment with antipsychotics in schizophrenia.

Authors:  Giuseppe Blasi; Alessandro Bertolino
Journal:  NeuroRx       Date:  2006-01

4.  Characterization of atypical antipsychotic drugs by a late decrease of striatal alpha1 spectral power in the electropharmacogram of freely moving rats.

Authors:  W Dimpfel
Journal:  Br J Pharmacol       Date:  2007-08-13       Impact factor: 8.739

5.  Changes in prefrontal and amygdala activity during olanzapine treatment in schizophrenia.

Authors:  Giuseppe Blasi; Teresa Popolizio; Paolo Taurisano; Grazia Caforio; Raffaella Romano; Annabella Di Giorgio; Fabio Sambataro; Valeria Rubino; Valeria Latorre; Luciana Lo Bianco; Leonardo Fazio; Marcello Nardini; Daniel R Weinberger; Alessandro Bertolino
Journal:  Psychiatry Res       Date:  2009-05-09       Impact factor: 3.222

6.  A Preliminary Study of Genetic Variation in the Dopaminergic and Serotonergic Systems and Genome-wide Additive Genetic Effects on Depression Severity and Treatment Response.

Authors:  Rohan H C Palmer; Christopher G Beevers; John E McGeary; Leslie A Brick; Valerie S Knopik
Journal:  Clin Psychol Sci       Date:  2016-10-19

7.  A neuroimaging study of emotion-cognition interaction in schizophrenia: the effect of ziprasidone treatment.

Authors:  Emmanuel Stip; Adel Cherbal; David Luck; Simon Zhornitsky; Lahcen Ait Bentaleb; Ovidiu Lungu
Journal:  Psychopharmacology (Berl)       Date:  2017-02-17       Impact factor: 4.530

8.  Treatment with olanzapine is associated with modulation of the default mode network in patients with Schizophrenia.

Authors:  Fabio Sambataro; Giuseppe Blasi; Leonardo Fazio; Grazia Caforio; Paolo Taurisano; Raffaella Romano; Annabella Di Giorgio; Barbara Gelao; Luciana Lo Bianco; Apostolos Papazacharias; Teresa Popolizio; Marcello Nardini; Alessandro Bertolino
Journal:  Neuropsychopharmacology       Date:  2009-12-02       Impact factor: 7.853

Review 9.  The mediodorsal thalamic nucleus and schizophrenia.

Authors:  Raúl Alelú-Paz; José Manuel Giménez-Amaya
Journal:  J Psychiatry Neurosci       Date:  2008-11       Impact factor: 6.186

10.  Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040.

Authors:  Eric Southam; Jackie Cilia; Jane E Gartlon; Marie L Woolley; Laurent P Lacroix; Carol A Jennings; Jane E Cluderay; Charlie Reavill; Claire Rourke; David M Wilson; Lee A Dawson; Andrew D Medhurst; Declan N C Jones
Journal:  Psychopharmacology (Berl)       Date:  2008-09-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.